Superior Planning, LLC’s Telix Pharmaceuticals TLX Stock Holding History

Superior Planning, LLC’s Portfolio TLX Stock Details TLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$14.4K	Buy	+1,314	New	+$14.9K	0.01%	802

Other funds holding TLX

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.6B AUM 22.09% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Private Advisor Group Morristown, New Jersey $29.9B AUM 19.22% 1-Year Est. Return

Raiffeisen Bank International Vienna, Austria $8.69B AUM 38.11% 1-Year Est. Return

Aubrey Capital Management Edinburgh, United Kingdom $115M AUM 51.42% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Brinker Capital Investments Berwyn, Pennsylvania $17.5B AUM 20.48% 1-Year Est. Return

Mariner Overland Park, Kansas $100B AUM 26.06% 1-Year Est. Return

Superior Planning, LLC's TLX Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in Telix Pharmaceuticals (TLX) in Q3 2026: 1,314 shares worth $14.4K. The stake represents 0.01% of the portfolio and ranks #802 among its holdings.

42 funds tracked by Wall St. Rank hold TLX as of Q3 2026.

Superior Planning, LLC held 1,314 shares of Telix Pharmaceuticals worth $14.4K as of Q3 2026.
Telix Pharmaceuticals was a new Superior Planning, LLC position in Q3 2026.
Telix Pharmaceuticals made up 0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #802 holding.
42 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.